RT
MODERATE EVIDENCEAlso known as: Retatrutide, GLP3-Reta, Triple agonist (GLP-1/GIP/glucagon)
Investigational — Phase 3 (not approved; anticipated ~2027)
Educational Overview
An investigational triple-agonist studied in large trials for weight and metabolic outcomes. Not FDA-approved and has no legal compounding pathway.
Research Mechanism
Agonism at GLP-1, GIP, and glucagon receptors; studied in the manufacturer's Phase 3 program.
Areas of Study
- Weight reduction (Phase 3 human trials)
- Metabolic endpoints
Safety Considerations
Investigational. Efficacy signals in trials are strong, but it is not approved and not legally available outside trials.
Frequently Asked Questions
Can I buy approved RT?
No. It is investigational; there is no approved or legal compounded version.
References
1 citations·1 with human data
Human RCT Verified
A phase 2 double-blind placebo-controlled trial in 338 adults reported least-squares mean body-weight change at 24 weeks of -17.5% in the 12mg group versus -1.6% with placebo. Gastrointestinal effects were the most common adverse events, mostly during dose escalation.
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023;389(6):514-526.NCT04881760
Citations are provided for educational reference. Study findings describe what was observed under the stated conditions and model, and do not imply any effect in humans or any recommended use.
Last reviewed: 2026-06-01 · Status: draft · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.